CapsoVision (NASDAQ:CV) Raised to Hold at Zacks Research

CapsoVision (NASDAQ:CV) was upgraded by equities researchers at Zacks Research to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Several other brokerages also recently commented on CV. Weiss Ratings reissued a “sell (e-)” rating on shares of CapsoVision in a research note on Wednesday, October 8th. Benchmark began coverage on shares of CapsoVision in a research report on Monday, July 28th. They set a “speculative buy” rating and a $5.00 price objective for the company. Roth Capital set a $7.00 price objective on shares of CapsoVision in a research note on Tuesday. Finally, Wall Street Zen upgraded shares of CapsoVision to a “hold” rating in a report on Sunday, July 13th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $6.00.

CapsoVision Trading Down 1.5%

Shares of CapsoVision stock traded down $0.07 on Wednesday, reaching $4.73. 15,524 shares of the stock were exchanged, compared to its average volume of 131,355. The firm’s 50 day simple moving average is $4.48. CapsoVision has a one year low of $3.43 and a one year high of $5.72.

CapsoVision (NASDAQ:CV) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($2.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($1.91). The company had revenue of $3.32 million for the quarter, compared to analyst estimates of $3.20 million.

Hedge Funds Weigh In On CapsoVision

A hedge fund recently bought a new stake in CapsoVision stock. New York State Common Retirement Fund acquired a new stake in CapsoVision, Inc. (NASDAQ:CV) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,114 shares of the company’s stock, valued at approximately $34,000.

About CapsoVision

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn’s disease.